H2A Developmental Core

肝细胞癌在非洲是一种非常常见和致命的癌症，作为艾滋病毒携带者的患者生活在非洲。 时间长了，肝细胞癌的负担可能会增加。在之前的研究中，我们的团队确认了慢性乙肝感染 C病毒(乙肝病毒、丙型肝炎病毒)、HIV和曼氏血吸虫病是肝细胞癌的独立危险因素。相比较 对美国来说，撒哈拉以南非洲的肝癌发生在较年轻和较晚期的患者中，仅 月份。Makerere大学的同事们提议在东非和西非建立伙伴关系 乌干达、塞内加尔范恩大学和约翰霍普金斯大学专注于艾滋病毒和肝细胞 非洲的癌症(肝癌)：H_2A联盟。建立在长期合作研究、指导的基础上 和临床活动，我们的首要目标是减轻亚洲区的肝癌负担 撒哈拉非洲。我们主张使用适当的医疗手段研究癌症拦截策略。 以阻断或逆转这些引起肝癌的感染的影响。我们将通过以下方式实现这一目标 发展地方能力，开展重要研究。H2 A学者奖提供了协同效应 为早期非洲调查人员提供资金，用于个人职业发展活动和接受指导的 利用实质性财团资源的试点项目。学者称号将每年轮换一次 乌干达和塞内加尔之间以及跨越国家和与霍普金斯大学建立联系的机会将积极 被追捕。我们向早期非洲调查人员提供实质性试点项目资源的做法 而将他们与霍普金斯大学的导师配对将使投资回报最大化。最终目的是要发展 一支才华横溢、合格的非洲研究人员队伍，担任艾滋病毒和肝癌研究领域的领导者。

Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only months. Proposed is an East and West African partnership between colleagues at Makerere University in Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub- Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by developing local capacity and performing important research. The H2A Scholar Award provides synergistic funding to early-stage African investigators for both individual career development activities and a mentored pilot project utilizing the substantive Consortium resources. Designation of Scholars will alternate yearly between Uganda and Senegal and opportunities to link across countries and with Hopkins will actively be pursued. Our approach of providing early-stage African investigators with substantive pilot project resources and pairing them with a Hopkins mentor will maximize the return on investment. The ultimate goal is to develop a cadre of talented, qualified African investigators to serve as leaders in the field of HIV and HCC research.